Other therapeutic options, such as IL-1 signaling inhibitor anakinra, have shown no difference in effectiveness compared with the standard of care in severe COVID-19 patients with pneumonia [153]. This evidence concerns the gene IL1A and susceptibility to pneumonia measurement.